Actinium Pharmaceuticals (ATNM) Shares Down 7.8%

Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) shares dropped 7.8% during mid-day trading on Monday . The stock traded as low as $0.58 and last traded at $0.59. Approximately 902,400 shares traded hands during mid-day trading, a decline of 18% from the average daily volume of 1,102,048 shares. The stock had previously closed at $0.64.

Several research analysts have recently weighed in on the stock. Zacks Investment Research raised shares of Actinium Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 price objective for the company in a report on Thursday, April 5th. Maxim Group set a $3.00 price objective on shares of Actinium Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, March 28th. Finally, B. Riley set a $3.00 price objective on shares of Actinium Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, March 14th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $3.70.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Worth Venture Partners LLC bought a new stake in Actinium Pharmaceuticals during the first quarter valued at approximately $140,000. Sio Capital Management LLC bought a new stake in Actinium Pharmaceuticals during the first quarter valued at approximately $393,000. Sabby Management LLC bought a new stake in Actinium Pharmaceuticals during the first quarter valued at approximately $729,000. Finally, Anson Funds Management LP bought a new stake in Actinium Pharmaceuticals during the first quarter valued at approximately $1,502,000.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older.

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply